An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

Conditions:   Recurrent Squamous Cell Carcinoma of Head;   Recurrent Squamous Cell Carcinoma of Neck;   Metastatic Squamous Cell Carcinoma of Head;   Metastatic Squamous Cell Carcinoma Neck
Intervention:   Drug: REGN2810
Sponsors:   Regeneron Pharmaceuticals;   Sanofi
Not yet recruiting - verified June 2017

http://ift.tt/2tWeUL7